Branched-chain amino acid levels are inversely associated with incident and prevalent chronic kidney disease in people with type 2 diabetes
- PMID: 38303102
- DOI: 10.1111/dom.15475
Branched-chain amino acid levels are inversely associated with incident and prevalent chronic kidney disease in people with type 2 diabetes
Abstract
Aim: To investigate the association of plasma metabolites with incident and prevalent chronic kidney disease (CKD) in people with type 2 diabetes and establish whether this association is causal.
Materials and methods: The Hoorn Diabetes Care System cohort is a large prospective cohort consisting of individuals with type 2 diabetes from the northwest part of the Netherlands. In this cohort we assessed the association of baseline plasma levels of 172 metabolites with incident (Ntotal = 462/Ncase = 81) and prevalent (Ntotal = 1247/Ncase = 120) CKD using logistic regression. Additionally, replication in the UK Biobank, body mass index (BMI) mediation and causality of the association with Mendelian randomization was performed.
Results: Elevated levels of total and individual branched-chain amino acids (BCAAs)-valine, leucine and isoleucine-were associated with an increased risk of incident CKD, but with reduced odds of prevalent CKD, where BMI was identified as an effect modifier. The observed inverse effects were replicated in the UK Biobank. Mendelian randomization analysis did not provide evidence for a causal relationship between BCAAs and prevalent CKD.
Conclusions: Our study shows the intricate relationship between plasma BCAA levels and CKD in individuals with type 2 diabetes. While an association exists, its manifestation varies based on disease status and BMI, with no definitive evidence supporting a causal link between BCAAs and prevalent CKD.
Keywords: cohort study; diabetic nephropathy; observational study; type 2 diabetes.
© 2024 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Feng XS, Farej R, Dean BB, et al. CKD prevalence among patients with and without type 2 diabetes: regional differences in the United States. Kidney Med. 2021;4(1):100385. doi:10.1016/j.xkme.2021.09.003
-
- Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322(13):1294‐1304. doi:10.1001/jama.2019.14745
-
- Lecamwasam A, Mansell T, Ekinci EI, Saffery R, Dwyer KM. Blood plasma metabolites in diabetes‐associated chronic kidney disease: a focus on lipid profiles and cardiovascular risk. Front Nutr. 2022;9:821209. doi:10.3389/fnut.2022.821209
-
- Yamaguchi Y, Zampino M, Moaddel R, et al. Plasma metabolites associated with chronic kidney disease and renal function in adults from the Baltimore longitudinal study of aging. Metabolomics. 2021;17(1):9. doi:10.1007/s11306‐020‐01762‐3
-
- Mahbub MH, Yamaguchi N, Nakagami Y, et al. Association of plasma branched‐chain and aromatic amino acids with reduction in kidney function evaluated in apparently healthy adults. J Clin Med. 2021;10(22):5234. doi:10.3390/jcm10225234
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
